Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

Figure 6

A, Efficacy of A-928605 and cetuximab, alone and in combination, in the MiaPaCa-2 pancreatic xenograft flank model. Beginning on day 16 post tumor cell injection, mice were dosed intraperitoneally with A-928605 at 37.5 mg/kg, b.i.d. for 20 days. Cetuximab and human IgG Control were dosed intraperitoneally at 30 mg/kg, once daily, 3×/week for a total of 6 doses. At the end of the dosing schedule, the %T/Cs (combination vs. vehicle and vs. human IgG control) were approximately 60 (P < 0.00001) and (combination vs. A-928605 + human IgG Control and vs. cetuximab) were approximately 72 (P < 0.05). B, Efficacy of A-928605 and erlotinib in combination in the HCC-827 NCSLC xenograft flank model. Beginning on day 20 post tumor cell injection, mice were dosed intraperitoneally with A-928605 at 37.5 mg/kg, b.i.d. for 16 days. Erlotinib was dosed orally at 3.1 mg/kg, b.i.d. for 16 days. At the end of the dosing schedule, the %T/Cs (combination vs. vehicle) was 17 (P < 0.00001) and (combination vs. erlotinib) was 27 (P < 0.005). In a separate arm of the study, A-928605 as a monotherapy was not consistently statistically different from its vehicle control (data not shown).

Back to article page